BERGENBIO LIMITED
Company number 10555293 · Monitor this company
Free AI analysis
Have an AI read this company's filings and write an assessment — financial health, risks, and what the numbers say.
Shareholders' funds
-£191
Balance sheet as at 2025-12-31
What it does
The company is involved in research and development in the biotechnology sector.
The company's own description, from its latest filed accounts.
Overview
- Company type
- Private Limited Company
- Incorporated
- 2017-01-10
- Employees
- 5 (2025 accounts · was 10 in 2024)
- Registered office
- 8 King Edward Street, Oxford, United Kingdom, OX1 4HL
- Postcode
- OX1 4HL
- Capital
- 100 GBP
- Accounts category
- Total Exemption Full
Accounts
- Last made up to
- 2025-12-31
- Next due by
- 2027-09-30
- Financial year end
- 31 December
Confirmation statement
- Last statement dated
- 2026-01-09
- Next due by
- 2027-01-23
Nature of business (SIC)
- 72110 Research and experimental development on biotechnology
Officers 1 current · 3 resigned
Group structure
Controlled by Bergenbio Asa (99221968) — since 2017-01-10
From persons-with-significant-control filings on the public register.
Contact details
- Website
- bergenbio.com
- Phone
- 0013711713
BerGenBio: Developing first-in-class AXL inhibitors for aggressive diseases, including advanced, treatment resistant cancers
The class of 2017
35%
of the 435 companies in this sector incorporated in 2017 are still active today; 61% have since been dissolved.
A fact about the year, not a forecast for this company.